Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Alexandra Kachaner, Raphaèle Seror, Fleur Cohen Aubart, Julien Henry, Thierry Lazure, et al.. Complete remission after a single bisphosphonate infusion in isolated bone Langerhans cell histiocytosis lesion: a case report and a narrative review of the literature. JBMR Plus, 2024, 8 (5), pp.ziae043. ⟨10.1093/jbmrpl/ziae043⟩. ⟨hal-04626829⟩
-
Robin Zagala, Nicolas Meyer, Philippe Saiag, Nora Kramkimel, Celeste Lebbe, et al.. Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network. Journal of the European Academy of Dermatology and Venereology, In press, ⟨10.1111/jdv.20155⟩. ⟨hal-04626767⟩
-
Johanne Seguin, Mostafa El Hajjam, Josette Legagneux, Sarah Diakhaby, Nathalie Mignet, et al.. Radiofrequency Combined with Intratumoral Immunotherapy: Preclinical Results and Safety in Metastatic Colorectal Carcinoma. Pharmaceutics, 2024, 16 (3), pp.315. ⟨10.3390/pharmaceutics16030315⟩. ⟨hal-04626840⟩
-
Julie Lecuelle, Caroline Truntzer, Debora Basile, Luigi Laghi, Luana Greco, et al.. Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts. EBioMedicine, 2024, 105, pp.105207. ⟨10.1016/j.ebiom.2024.105207⟩. ⟨hal-04626841⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
Mots clés
Assisted reproductive techniques
Dabrafenib
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Radiotherapy
Body mass index
Circulating tumor DNA
Adverse events
Histiocytosis
Biomarkers
Non-small cell lung cancer
Osimertinib
Plasma
EGFR
Systemic therapy
Diagnosis
Immune checkpoint inhibitor
Metastatic
Immunomodulation
ADN tumoral circulant
Colon cancer
Anti-PD-1
Colorectal cancer
Adjuvant FOLFOX
Immunohistochemistry
Surgical excision
BRAF
Melanoma
Prognostic
Chemoresistance
Anti-PD-1 antibody
Cemiplimab
Immunotherapy
Antineoplastic agents
Crizotinib
Liver metastases
Gastric bypass
Prognosis
Acute generalized exanthematous pustulosis
Advanced
ACTH
Locally advanced
Beta-catenin
Adjuvant therapy
Adjuvant
Cancer
Androgen insensitivity
AML
TNM classification
Bisphosphonates
Survival
Children
Oncology
Invasive cutaneous squamous cell carcinoma
Treatment
Staging
BRAFV600-mutant melanoma
Resistance
Bariatric surgery
Biomarker
Anti-Tumor pharmacology
AZD9291
Abdominal pain
Trametinib
Wnt
Chemotherapy
Metastatic cSCC
Anti-PD1 blockade
2-chlorodeoxyadenosine
ALK
Cancer bronchique non à petites cellules
Lung adenocarcinoma
Sonic Hedgehog
Merkel cell carcinoma
Allelic imbalance
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Circulating cell-free DNA
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
ALK rearrangement
BRAFV600E
Safety
Colorectal carcinoma
Abscopal effect
Targeted therapy
Prevention
Follow-up
Anti-PD1
Antibody-drug conjugate
Nivolumab
Advanced melanoma
Anti-CTLA-4
Biliopancreatic diversion
Langerhans cell histiocytosis
Molecular targeted therapies
BRAF V600E
BRAF V600-mutation
Polyomavirus
Cutaneous squamous cell carcinoma
BRAFV600E mutation
Radiofrequency ablation
Mesenchymal stromal cells